Tuesday 12 November 2024 – During Global Biosimilars Week, we recognise the role of biosimilars in providing patients with affordable access to essential medicines.

Our collaboration with Celltrion stands as a testament to our shared commitment to enhancing patient access to essential medicines. We combine their world-class technical expertise with our deeply established commercial presence across MENA, ensuring that patients receive innovative and reliable treatments. Our profound understanding of the regional healthcare landscape, including navigating the complex regulatory environment, enables us to introduce products like these to patients, which not only provides cost-effective alternatives, but also promotes healthier communities by bridging gaps in healthcare availability.

In addition to expanding treatment options, we are dedicated to fostering a deeper understanding and acceptance of biosimilars among healthcare professionals. Through initiatives like the ASHP-accredited BioReach Programme, we empower healthcare professionals with the knowledge and confidence needed to prescribe these therapies effectively. By enhancing educational efforts, we aim to accelerate the adoption of biosimilars, ultimately leading to improved patient health outcomes.

As we celebrate Global Biosimilars Week, we reaffirm our commitment to continue forming strategic partnerships that will broaden access to care. Our goal remains ensuring that we put better health within reach, every day.